Nrx Pharmaceuticals, Inc. (Nasdaq: Nrxp, Nrx Pharmaceuticals), ("Nrxp" Or The "Company"), A Clinical-Stage Biopharmaceutical Company, Today Announced That The U.S. Food And Drug Administration (Fda) Denied The Breakthrough Therapy Designation (Btd) Request For Zyesami
